Biologically Active Small Molecules

A slow, tight binding, competitive aminopeptidase (AP) inhibitor, first described as an inhibitor of AP-A (glutamyl AP IC₅₀ = 0.54 &microg/ml) but not of AP-B (arginine AP) also inhibits AP-N (AP-M, alanyl AP Ki = 20-200 nM),

A slow, tight binding, competitive aminopeptidase (AP) inhibitor, first described as an inhibitor of AP-A (glutamyl AP IC₅₀ = 0.54 &microg/ml) but not of AP-B (arginine AP) also inhibits AP-N (AP-M, alanyl AP Ki = 20-200 nM),

A slow, tight binding, competitive aminopeptidase (AP) inhibitor, first described as an inhibitor of AP-A (glutamyl AP IC₅₀ = 0.54 &microg/ml) but not of AP-B (arginine AP) also inhibits AP-N (AP-M, alanyl AP Ki = 20-200 nM),

AMC-AA is one of several fatty acid amides which can be used to measure FAAH activity. Exposure of AMC-AA to FAAH results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm, allowing for fast and

AMC-AA is one of several fatty acid amides which can be used to measure FAAH activity. Exposure of AMC-AA to FAAH results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm, allowing for fast and

AMC-AA is one of several fatty acid amides which can be used to measure FAAH activity. Exposure of AMC-AA to FAAH results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm, allowing for fast and

AMC-AA is one of several fatty acid amides which can be used to measure FAAH activity. Exposure of AMC-AA to FAAH results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm, allowing for fast and

Blocks the cell surface binding of the CXCR4 ligand CXCL12 (IC50 = 18 nM), inhibits calcium mobilization (IC50 = 4 nM), and (at 6,250 nM) completely blocks chemotaxis of SupT1 cells active against various HIV strains (IC50s = 6-12 nM).

Blocks the cell surface binding of the CXCR4 ligand CXCL12 (IC50 = 18 nM), inhibits calcium mobilization (IC50 = 4 nM), and (at 6,250 nM) completely blocks chemotaxis of SupT1 cells active against various HIV strains (IC50s = 6-12 nM).

Blocks the cell surface binding of the CXCR4 ligand CXCL12 (IC50 = 18 nM), inhibits calcium mobilization (IC50 = 4 nM), and (at 6,250 nM) completely blocks chemotaxis of SupT1 cells active against various HIV strains (IC50s = 6-12 nM).

A multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC₅₀s = 2, 3, 6, 8, 84, and 59 nM, respectively) blocks VEGF-induced angiogenesis in the rat corneal

A multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC₅₀s = 2, 3, 6, 8, 84, and 59 nM, respectively) blocks VEGF-induced angiogenesis in the rat corneal